CA088-1005

A Phase 1, Multicenter, Open-label Study to Evaluate the Safety and Preliminary Efficacy of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma and Determine the Recommended Dose for Each Add-on Investigational Component

Myeloma Service

Arms / Cohorts

Experimental, Arm B:Part 1: BMS-986393 + Mezigdomide

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental, Arm C:Part 1: BMS-986393 + Iberdomide

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Accepting patients

Experimental, Arm B:Part 2: BMS-986393 + Mezigdomide

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Not yet accepting

Experimental, Arm C:Part 2: BMS-986393 + Iberdomide

Status
Status not available
Treatments
Treatments not available
Criteria
Criteria not available

Not yet accepting

Patient Screener(888) 828-2206

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print a patient-friendly report to share with your patient.

We can help answer any questions and connect you (or your patient) with the study team.

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.